Fig. 7: TPX2 promotes the resistance of HCC cells to sorafenib in an intrahepatic subcutaneous tumor model. | Cell Death & Disease

Fig. 7: TPX2 promotes the resistance of HCC cells to sorafenib in an intrahepatic subcutaneous tumor model.

From: TPX2 enhances the transcription factor activation of PXR and enhances the resistance of hepatocellular carcinoma cells to antitumor drugs

Fig. 7

The HepG2 cells were transfected with control, TPX2 or siTPX2 and injected into the subcutaneous position of nude mice. The tumor tissues were prepared as the micro-blocks for constructing the intrahepatic HCC model. The mice received the 1.0 mg/kg concentration of sorafenib via oral administration. The results were shown as images of micro positron emission tomography (microPET) (A) or quantitative results. *P < 0.05.

Back to article page